glycopyrronium bromide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4302 596-51-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sialanar
  • NVA237
  • Seebri Breezhaler
  • glycopyrronium bromide
  • copyrrolate
  • gastrodyn
  • glycopyrrolate
  • robanul
  • glycopyrronium
  • glycopyrrolate bromide
Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.
  • Molecular weight: 318.44
  • Formula: C19H28NO3
  • CLOGP: 0.12
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.57
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O
0.30 mg P
3 mg R
44 mcg Inhal.powder

ADMET properties:

PropertyValueReference
BA (Bioavailability) 17 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.37 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16.80 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.65 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 11, 1961 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 394.21 30.85 87 480 11227 2346291
Dyspnoea 387.95 30.85 128 439 78605 2278913
Cough 338.10 30.85 95 472 33022 2324496
Obstructive airways disorder 165.58 30.85 30 537 1343 2356175
Forced expiratory volume decreased 163.69 30.85 26 541 519 2356999
Pneumonia 142.62 30.85 55 512 49241 2308277
Productive cough 135.51 30.85 32 535 5289 2352229
Wheezing 129.71 30.85 32 535 6352 2351166
Chronic obstructive pulmonary disease 126.44 30.85 32 535 7045 2350473
Product use in unapproved indication 125.56 30.85 35 532 11165 2346353
Malaise 122.39 30.85 51 516 55534 2301984
Sputum discoloured 118.04 30.85 22 545 1144 2356374
Drug ineffective 107.30 30.85 56 511 101568 2255950
Total lung capacity increased 95.99 30.85 11 556 9 2357509
Lower respiratory tract infection 74.76 30.85 20 547 5404 2352114
Nasopharyngitis 71.79 30.85 27 540 22029 2335489
Hypertension 69.60 30.85 28 539 27333 2330185
Blood pressure systolic increased 69.57 30.85 16 551 2323 2355195
Throat irritation 66.72 30.85 18 549 5012 2352506
Sleep apnoea syndrome 65.68 30.85 15 552 2111 2355407
Frustration tolerance decreased 61.05 30.85 12 555 821 2356697
Blood pressure increased 59.61 30.85 22 545 16964 2340554
Respiration abnormal 57.96 30.85 11 556 625 2356893
Pyrexia 57.22 30.85 30 537 53678 2303840
Headache 56.20 30.85 34 533 80145 2277373
Dyspnoea exertional 55.38 30.85 16 551 5704 2351814
Chest discomfort 55.26 30.85 20 547 14575 2342943
Pulmonary function test decreased 54.11 30.85 10 557 491 2357027
Tachycardia 52.97 30.85 20 547 16389 2341129
Chest pain 52.08 30.85 23 544 28114 2329404
Pulmonary thrombosis 51.61 30.85 11 556 1123 2356395
Lung disorder 49.72 30.85 15 552 6197 2351321
Fall 49.22 30.85 26 541 47073 2310445
Weight decreased 48.69 30.85 22 545 28349 2329169
Nasal congestion 48.03 30.85 15 552 6951 2350567
Oropharyngeal pain 44.36 30.85 16 551 11502 2346016
Influenza 42.50 30.85 16 551 12962 2344556
Anxiety 41.75 30.85 20 547 29339 2328179
Anaphylactic reaction 39.31 30.85 14 553 9691 2347827
Blood test abnormal 39.06 30.85 9 558 1309 2356209
Dizziness 38.69 30.85 24 543 58641 2298877
Bronchitis 38.09 30.85 15 552 13699 2343819
Fatigue 37.39 30.85 27 540 84846 2272672
Depression 36.47 30.85 18 549 28114 2329404
Pulmonary mass 35.67 30.85 9 558 1917 2355601
Arthritis 35.21 30.85 13 554 9955 2347563
Bradycardia 35.19 30.85 13 554 9968 2347550
Glaucoma 34.92 30.85 9 558 2086 2355432
Insomnia 34.92 30.85 17 550 25770 2331748
Oxygen saturation decreased 34.76 30.85 12 555 7574 2349944
Condition aggravated 34.29 30.85 18 549 31961 2325557
Blood count abnormal 34.16 30.85 9 558 2273 2355245
Heart rate increased 33.84 30.85 13 554 11092 2346426
Cardiac arrest 33.45 30.85 14 553 14916 2342602
Hypoventilation 33.16 30.85 7 560 680 2356838
Product use issue 32.69 30.85 13 554 12156 2345362
Hyper IgE syndrome 32.56 30.85 4 563 9 2357509
Nasal inflammation 31.10 30.85 5 562 106 2357412
Rhinorrhoea 31.04 30.85 11 556 7489 2350029

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyspnoea 189.91 36.16 73 370 51986 1694352
Chronic obstructive pulmonary disease 164.32 36.16 40 403 5913 1740425
Cough 138.22 36.16 45 398 19152 1727186
Asthma 115.07 36.16 29 414 4875 1741463
Wheezing 89.61 36.16 23 420 4130 1742208
Chest discomfort 85.45 36.16 25 418 7306 1739032
Forced expiratory volume decreased 79.18 36.16 14 429 414 1745924
Urinary retention 52.32 36.16 16 427 5379 1740959
Tachycardia 49.55 36.16 19 424 12609 1733729
Productive cough 49.53 36.16 14 429 3577 1742761
Dyspnoea exertional 47.49 36.16 14 429 4147 1742191
Blood pressure increased 45.12 36.16 17 426 10736 1735602
Pneumonia 43.62 36.16 26 417 46156 1700182
Dyspnoea at rest 43.04 36.16 8 435 312 1746026
Product use in unapproved indication 39.88 36.16 15 428 9407 1736931
Cardiorenal syndrome 38.01 36.16 6 437 86 1746252
Product use issue 37.56 36.16 14 429 8557 1737781

Pharmacologic Action:

SourceCodeDescription
ATC A03AB02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, quaternary ammonium compounds
ATC D11AA01 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Antihidrotics
ATC R03BB06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Anticholinergics
ATC A03CA05 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
Synthetic anticholinergic agents in combination with psycholeptics
ATC R03AL04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL07 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL09 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL11 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL12 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
MeSH PA D000759 Adjuvants, Anesthesia
FDA EPC N0000175574 Anticholinergic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Chronic obstructive lung disease indication 13645005 DOID:3083
General anesthesia indication 50697003
Excessive salivation indication 53827007
Vagal Reflex Bradycardia indication
Irritable bowel syndrome off-label use 10743008 DOID:9778
Diarrhea off-label use 62315008
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Hiatal hernia contraindication 84089009 DOID:12642
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 7820694 June 2, 2020 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 8067437 June 2, 2020 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 8283362 June 2, 2020 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 8658673 June 2, 2020 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH SEEBRI NOVARTIS N207923 Oct. 29, 2015 DISCN POWDER INHALATION 7229607 April 9, 2021 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH SEEBRI NOVARTIS N207923 Oct. 29, 2015 DISCN POWDER INHALATION 8029768 April 9, 2021 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 7229607 April 9, 2021 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 8029768 April 9, 2021 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
1MG/5ML CUVPOSA MERZ PHARMS N022571 July 28, 2010 RX SOLUTION ORAL 7638552 Aug. 20, 2023 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
1MG/5ML CUVPOSA MERZ PHARMS N022571 July 28, 2010 RX SOLUTION ORAL 7816396 Aug. 20, 2023 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
15.6MCG/INH UTIBRON NOVARTIS N207930 Oct. 29, 2015 DISCN POWDER INHALATION 6878721 Feb. 25, 2025 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 8324266 May 28, 2030 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 8703806 May 28, 2030 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 8808713 May 28, 2030 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 9415009 May 28, 2030 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 9463161 May 28, 2030 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.0090MG/INH BEVESPI AEROSPHERE ASTRAZENECA PHARMS N208294 April 25, 2016 RX AEROSOL, METERED INHALATION 8815258 March 17, 2031 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
25MCG/ML LONHALA MAGNAIR KIT SUNOVION RESP N208437 Dec. 5, 2017 RX SOLUTION INHALATION Dec. 5, 2020 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.69 SCIENTIFIC LITERATURE CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 9.25 SCIENTIFIC LITERATURE IUPHAR
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.64 SCIENTIFIC LITERATURE CHEMBL
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Ki 9.06 SCIENTIFIC LITERATURE IUPHAR
Muscarinic acetylcholine receptor M5 GPCR ANTAGONIST Ki 8.91 SCIENTIFIC LITERATURE IUPHAR

External reference:

IDSource
D006024 MESH_DESCRIPTOR_UI
4018421 VUID
N0000146747 NUI
C0017970 UMLSCUI
D00540 KEGG_DRUG
387122008 SNOMEDCT_US
DB00986 DRUGBANK_ID
V92SO9WP2I UNII
1038 INN_ID
51186-83-5 SECONDARY_CAS_RN
CHEBI:90972 CHEBI
CHEMBL1201027 ChEMBL_ID
CHEMBL1201335 ChEMBL_ID
11693 PUBCHEM_CID
7459 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1250 TABLET 1 mg ORAL ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1251 TABLET 2 mg ORAL ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9584 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9585 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9586 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9587 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9679 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9680 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9681 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9682 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Cuvposa HUMAN PRESCRIPTION DRUG LABEL 1 0259-0501 LIQUID 1 mg ORAL NDA 18 sections
BEVESPI AEROSPHERE HUMAN PRESCRIPTION DRUG LABEL 2 0310-4600 AEROSOL, METERED 9 ug RESPIRATORY (INHALATION) NDA 18 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0517-4601 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0517-4602 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0517-4605 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0517-4620 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8170 TABLET 1 mg ORAL ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6033 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6034 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6035 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6036 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Robinul HUMAN PRESCRIPTION DRUG LABEL 1 0641-6104 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Robinul HUMAN PRESCRIPTION DRUG LABEL 1 0641-6105 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Robinul HUMAN PRESCRIPTION DRUG LABEL 1 0641-6106 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Robinul HUMAN PRESCRIPTION DRUG LABEL 1 0641-6107 INJECTION 0.20 mg INTRAMUSCULAR NDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0722-7097 TABLET 1.50 mg ORAL ANDA 11 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3825 INJECTION 0.20 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3827 INJECTION 0.40 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3829 INJECTION 1 mg INTRAMUSCULAR ANDA 12 sections
Glycopyrrolate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3831 INJECTION 4 mg INTRAMUSCULAR ANDA 12 sections